Data Mining or real results CLSN reported a failure in its overall phase 3 study. A substantial subset of the data indicates that they have an effective process. Can someone help evaluate this situation? Is this subset valid? Will the FDA give it any credence? What is the next step for the company? Is it an interesting spec @ $1.00? Any feedback is appreciated.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.